Compare Stocks → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ENLVNASDAQ:EQNASDAQ:GNPXNASDAQ:PHASNASDAQ:ZYNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENLVEnlivex Therapeutics$3.95+2.3%$3.25$1.20▼$4.37$73.35M1.0193,611 shs90,525 shsEQEquillium$2.42+17.5%$1.95$0.45▼$3.25$85.33M1.64370,758 shs177,604 shsGNPXGenprex$2.83+4.4%$5.32$2.50▼$46.00$4.22M-0.5781,798 shs8,168 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shs3,900 shsZYNEZynerba Pharmaceuticals$1.30+2.4%$1.30$0.25▼$1.40$70.12M1.32515,333 shs862,700 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENLVEnlivex Therapeutics-1.28%-3.98%+28.67%+49.61%+11.88%EQEquillium0.00%-28.47%-25.90%+202.94%+187.67%GNPXGenprex-0.36%-8.39%-39.06%-70.33%-92.66%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%-98.57%+25.00%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%+209.52%Urgent: Protect Your Investments from a Chinese Invasion (Ad)An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENLVEnlivex Therapeutics1.9981 of 5 stars3.53.00.00.02.30.80.6EQEquillium1.3756 of 5 stars3.52.00.00.01.91.70.0GNPXGenprex4.224 of 5 stars3.52.00.04.72.50.81.3PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENLVEnlivex Therapeutics3.00Buy$12.00203.80% UpsideEQEquillium3.00Buy$3.4040.50% UpsideGNPXGenprex3.00Buy$10.00253.36% UpsidePHASPhaseBio PharmaceuticalsN/AN/AN/AN/AZYNEZynerba Pharmaceuticals2.25Hold$1.11-14.62% DownsideCurrent Analyst RatingsLatest PHAS, EQ, ENLV, GNPX, and ZYNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENLVEnlivex TherapeuticsN/AN/AN/AN/A$3.09 per shareN/AEQEquillium$36.08M2.37N/AN/A$0.93 per share2.60GNPXGenprexN/AN/AN/AN/A$18.55 per shareN/APHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00ZYNEZynerba PharmaceuticalsN/AN/AN/AN/A$1.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENLVEnlivex Therapeutics-$31.06M-$1.47N/AN/AN/AN/A-57.02%-47.73%3/29/2024 (Estimated)EQEquillium-$62.43M-$0.39N/AN/AN/A-36.96%-51.82%-22.57%5/9/2024 (Estimated)GNPXGenprex-$23.74M-$24.80N/AN/AN/AN/A-194.71%-156.61%3/29/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/AZYNEZynerba Pharmaceuticals-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENLVEnlivex TherapeuticsN/A7.347.34EQEquilliumN/A1.791.91GNPXGenprexN/A2.962.96PHASPhaseBio PharmaceuticalsN/A0.470.47ZYNEZynerba PharmaceuticalsN/A3.433.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENLVEnlivex Therapeutics1.02%EQEquillium27.05%GNPXGenprex14.05%PHASPhaseBio Pharmaceuticals49.02%ZYNEZynerba Pharmaceuticals11.23%Insider OwnershipCompanyInsider OwnershipENLVEnlivex Therapeutics12.28%EQEquillium30.00%GNPXGenprex11.54%PHASPhaseBio Pharmaceuticals9.90%ZYNEZynerba Pharmaceuticals13.04%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableENLVEnlivex Therapeutics5018.57 million16.29 millionOptionableEQEquillium4535.26 million24.58 millionNot OptionableGNPXGenprex311.49 million1.32 millionOptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableZYNEZynerba Pharmaceuticals2553.94 million46.91 millionOptionablePHAS, EQ, ENLV, GNPX, and ZYNE HeadlinesSourceHeadlineHarmony Biosciences Reports Strong Third Quarter 2023 Financial Resultsfinance.yahoo.com - October 31 at 7:57 AMWhy Shares of Harmony Bioscience Are Falling on Fridayfool.com - October 13 at 12:59 PMNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapiesmarkets.businessinsider.com - October 11 at 9:47 AMHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEfinance.yahoo.com - October 11 at 9:47 AMH.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 10 at 1:59 PMAnalysts: ZYNE stock price target of $1.25 in 12 monthsknoxdaily.com - October 5 at 6:47 PMImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructionsfinance.yahoo.com - October 4 at 7:33 PMExamining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 2 at 3:14 PM20 Countries With Highest Rate of Epilepsyfinance.yahoo.com - September 29 at 6:24 PMZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023finance.yahoo.com - September 29 at 1:23 PMHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealbizjournals.com - September 27 at 2:42 PMZynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Riseknoxdaily.com - September 25 at 8:15 PMZynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwrightknoxdaily.com - September 20 at 12:12 PMNegative sentiment towards ZYNE reflected in surge in short interestknoxdaily.com - September 15 at 8:27 PMInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Incfinance.yahoo.com - September 14 at 11:23 PMZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposiumfinance.yahoo.com - September 14 at 6:23 PMZynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statementlaw.com - September 11 at 4:04 PMPositive sentiment towards ZYNE reflected in decline in short interestknoxdaily.com - September 8 at 5:19 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLRbakersfield.com - August 31 at 5:00 PMHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)msn.com - August 16 at 4:20 AMHarmony Makes Rare Disease Play with Potential $200M Zynerba Buyoutbiospace.com - August 15 at 6:19 PMZynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much?dhakatribune.com - August 15 at 6:19 PMIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - August 15 at 6:19 PMZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEmarketwatch.com - August 14 at 9:48 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways3 wealth-compounding stocks to beat the market this decadeFebruary 28, 2024 7:00 AMView 3 wealth-compounding stocks to beat the market this decadeThis Industrial Products Stock is Goldman’s Favorite This CycleMarch 11, 2024 9:55 AMView This Industrial Products Stock is Goldman’s Favorite This Cycle3 Real Estate Stocks to Buy on Commission CutsMarch 20, 2024 6:15 AMView 3 Real Estate Stocks to Buy on Commission CutsOversold and Diverging, Chewy Stock is Ready to ReboundMarch 22, 2024 6:10 AMView Oversold and Diverging, Chewy Stock is Ready to ReboundAll Headlines Company DescriptionsEnlivex TherapeuticsNASDAQ:ENLVEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.EquilliumNASDAQ:EQEquillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Zynerba PharmaceuticalsNASDAQ:ZYNEZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.